IP Library Granted Patent US 7,553,941
Granted Patent B2
US 7,553,941 · App. 11/700,911 · Granted Jun 30, 2009

Long-acting polypeptides and methods of producing same

Assignee: Modigene Inc
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,553,941
App. No.
11/700,911
Granted
Jun 30, 2009
Kind
B2
Abstract

A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.

Claims (14)

1. A polypeptide consisting of an hGH protein, a single chorionic gonadotrophin carboxy terminal peptide or a truncated single chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide, and two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide.

2. The polypeptide of claim 1 , wherein the sequence of at least one of said chorionic gonadotrophin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:17 and SEQ ID NO:18.

3. The polypeptide of claim 1 , wherein at least one chorionic gonadotrophin carboxy terminal peptide is truncated.

4. The polypeptide of claim 1 , wherein said hGH is glycosylated.

5. The polypeptide of claim 1 , wherein said hGH is non-glycosylated.

6. The polypeptide of claim 1 , wherein at least one chorionic gonadotrophin carboxy terminal peptide is glycosylated.

7. The polypeptide of claim 1 , wherein the sequence of said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41.

8. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

9. A polypeptide consisting of an hGH polypeptide, a single chorionic gonadotrophin carboxy terminal peptide or a truncated single chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide, and two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide, wherein at least one chorionic gonadotrophin carboxy terminal peptide is attached to said hGH polypeptide via a linker.

10. The polypeptide of claim 9 , wherein said linker is a peptide bond.

11. A polypeptide consisting of an hGH polypeptide, a single chorionic gonadotrophin carboxy terminal peptide or a truncated single chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said hGH polypeptide, and two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said hGH polypeptide and a signal peptide attached to the amino terminus of said one chorionic gonadotrophin carboxy terminal peptide.

12. The polypeptide of claim 11 , wherein said signal peptide is as set forth in SEQ ID NO: 19.

13. A method of improving a biological half life of an hGH polypeptide, comprising the step of attaching one chorionic gonadotrophin carboxy terminal peptide to the amino terminus of said hGH polypeptide and two chorionic gonadotrophin carboxy terminal peptides to the carboxy terminus of said hGH polypeptide, thereby improving the biological half life of the hGH polypeptide.

14. The method of claim 13 , wherein the sequence of at least one chorionic gonadotrophin carboxy terminal peptide comprises an amino acid sequence selected from the sequences as set forth in SEQ ID NO: 17 and SEQ ID NO: 18.

Assignments (9)
SECURITY INTEREST Recorded Jul 17, 2024
From: OPKO BIOLOGICS LTD.
To: HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 068407/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: PROLOR BIOTECH, LLC
To: OPKO BIOLOGICS LTD.
Reel/Frame 064679/0746 →
CHANGE OF NAME Recorded May 23, 2014
From: PROLOR BIOTECH LTD.
To: OPKO BIOLOGICS LTD.
Reel/Frame 033015/0859 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT RECEIVING PARTY DATA NAME: MODIGENE INC, AND ADDRESS: 8000 TOWERS CRESCENT DRIVE, SUITE 1300, VIENNA, VA 22182 PREVIOUSLY RECORDED ON REEL 021560 FRAME 0605. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT RECEIVING PARTY DATA NAME: MODIGENETECH LTD AND ADDRESS: 3 PINCHAS SAPIR, KIRYAT WEIZMANN, NES ZIONA, 74140, ISRAEL. Recorded Aug 7, 2013
From: FARES, FUAD; FARES, UDI EYAL
To: MODIGENETECH LTD.
Reel/Frame 030983/0949 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT RECEIVING PARTY DATA NAME: MODIGENETECH INC AND ADDRESS: 8000 3 PINCHAS SAPIR, KIRYAT WEIZMANN, NES ZIONA, 74140 PREVIOUSLY RECORDED ON REEL 021560 FRAME 0605. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT RECEIVING PARTY DATA NAME: MODIGENETECH LTD AND ADDRESS: 3 PINCHAS SAPIR,KIRYAT WEIZMANN, NES ZIONA, 74140, ISRAEL. Recorded Aug 7, 2013
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENETECH LTD
Reel/Frame 030983/0780 →
CHANGE OF NAME Recorded May 16, 2012
From: MODIGENETECH LTD.
To: PROLOR BIOTECH LTD.
Reel/Frame 028214/0675 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 022577 FRAME 0311. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE'S CORRECT NAME IS MODIGENETECH LTD.. Recorded Apr 13, 2010
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENETECH LTD.
Reel/Frame 024221/0063 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 021560 FRAME 0605. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE INTEREST. Recorded Apr 22, 2009
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENE INC
Reel/Frame 022577/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2008
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENE INC
Reel/Frame 021560/0605 →
Continuity (2)
Provisional Application 6076476100 · Feb 3, 2006
Related Publication 20070190611A1 · Aug 16, 2007